Antifungal treatment strategies in patients with haematological diseases or cancer: from prophylaxis to empirical, pre-emptive and targeted therapy.
about
Development of a novel inhalational model of invasive pulmonary aspergillosis in rats and comparative evaluation of three biomarkers for its diagnosis.Invasive candidiasis in critical care setting, updated recommendations from "Invasive Fungal Infections-Clinical Forum", Iran.Combining standard clinical methods with PCR showed improved diagnosis of invasive pulmonary aspergillosis in patients with hematological malignancies and prolonged neutropeniaDiagnostic methods for invasive fungal diseases in patients with hematologic malignanciesLaboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcomePharmacoeconomics of empirical antifungal use in febrile neutropenic hematological malignancy and hematopoietic stem cell transplant patients.In Vitro and In Vivo Evaluation of Small Cationic Abiotic Lipopeptides as Novel Antifungal Agents.Micafungin for empirical antifungal therapy in patients with febrile neutropenia: multicenter phase 2 study.Micafungin as empirical antifungal therapy in hematological patients: a retrospective, multicenter study in the Czech and Slovak Republics.Concomitant occurrence of itraconazole-resistant and -susceptible strains of Aspergillus fumigatus in routine cultures.Preemptive Antifungal Therapy for Febrile Neutropenic Hematological Malignancy Patients in China.Incidence and outcomes of invasive fungal disease in adult patients with acute lymphoblastic leukemia treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone: implications for prophylaxis.Candida Species Biofilms' Antifungal Resistance.Environmental study of azole-resistant Aspergillus fumigatus with TR34/L98H mutations in the cyp51A gene in Iran.
P2860
Q33793571-CBFC6E51-D5B2-4042-8B26-F68520DD209DQ34452343-544113BC-3939-4931-9EB6-C72D8F8AB2D3Q35678982-3350E445-BD11-49F3-B6E6-287C8304D7CAQ36584898-5B703782-1E5E-45FE-9D70-BC411D3D2EB0Q37287794-05425BC1-9143-4C46-BBCA-A9F6C015C4F7Q38097528-5D4AC0EB-16B8-40A8-8DFE-A022965239E0Q38899042-32647F8F-68A8-4A47-8112-6F223066B8ECQ40241173-274BFC21-2F8B-4909-926B-6B019BFD0210Q40270696-8CD041B6-0EE3-4EA1-B810-99A9957E5ABAQ41696923-286A4E76-5BE8-4D58-B6B4-CBBC06DFB613Q42368519-8D33617B-9185-4B8D-B984-46ADBABD2F15Q45735890-74B8FEA0-BDFC-4676-9433-55D22C18F7B2Q48163282-2A4041DD-331F-4872-8A61-3568BA40B992Q50998294-0DF46519-4A25-474A-8F44-A1AAC7501CD5
P2860
Antifungal treatment strategies in patients with haematological diseases or cancer: from prophylaxis to empirical, pre-emptive and targeted therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antifungal treatment strategie ...... -emptive and targeted therapy.
@en
Antifungal treatment strategie ...... -emptive and targeted therapy.
@nl
type
label
Antifungal treatment strategie ...... -emptive and targeted therapy.
@en
Antifungal treatment strategie ...... -emptive and targeted therapy.
@nl
prefLabel
Antifungal treatment strategie ...... -emptive and targeted therapy.
@en
Antifungal treatment strategie ...... -emptive and targeted therapy.
@nl
P2093
P2860
P1433
P1476
Antifungal treatment strategie ...... -emptive and targeted therapy.
@en
P2093
Agata Mikolajewska
Markus Ruhnke
Stefan Schwartz
P2860
P356
10.1111/J.1439-0507.2010.01961.X
P577
2011-05-09T00:00:00Z